z-logo
open-access-imgOpen Access
Clinicopathological Analysis of 90 Cases of Polyacrylamide Hydrogel Injection for Breast Augmentation Including 2 Cases Followed by Breast Cancer
Author(s) -
Ying Yang,
Shumo Li,
Jia He,
Xin Zhao,
Wei Chen,
Xiaoming Dai,
Liu Liu
Publication year - 2019
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000499832
Subject(s) - medicine , breast cancer , ductal carcinoma , atrophy , cancer , surgery
Background: Although polyacrylamide hydrogel (PAAG) injection for breast augmentation has been prohibited for many years, the long-term complications will be significant for a long period. Few research articles have focused on the clinicopathological analysis. Materials and Methods: We summarized clinical and pathological features of 90 cases after PAAG-injected breast augmentation, including 2 cases of breast cancer developed following PAAG injection. Results: All patients were females between the ages of 30 and 64 years (mean, 44 years). The complications included masses (75.58%), pain (45.35%), migration (22.09%), deformation (18.60%), infection (16.28%), induration (4.65%), and psychological fear (2.33%). Microscopically, the PAAG presented as purple gel pools, and the foreign body reaction was noted in all 90 patients. The proportion of fibrous component exceeded 90% in 26 cases (28.89%). Chronic and acute inflammation was noted in 70 (77.78%) and 9 (10%) patients, respectively. The mammary gland around the gel displayed atrophy in 18 cases (20.00%), adenosis in 33 cases (36.67%), ductal carcinoma in situ in 1 case (1.11%), and invasive carcinoma in 1 case (1.11%). Conclusion: The long-term complications of PAAG-injected breast augmentation are various and complex. Pathologically, these complications are associated with foreign body reaction, fibrosis, and inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here